XML 42 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Note 1 - Significant Accounting Policies - Summary of Revenues (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2019
Revenues $ 49,959 $ 2,871 $ 69,018 $ 7,694  
Torii Pharmaceutical Co. [Member]          
Revenues       1,335 $ 20,101
Product [Member]          
Revenues 33,430 0 51,301 218  
Product [Member] | ORLADEYO [Member]          
Revenues 28,374 0 39,312 0  
Product [Member] | PERAMIVIR [Member]          
Revenues 434 0 7,254 218  
Product [Member] | RAPIVAB [Member]          
Revenues 4,622 0 4,735 0  
Royalty [Member]          
Revenues 128 44 (769) 1,989  
Milestone [Member]          
Revenues 15,000 0 15,000 0  
Collaborative and Other Research and Development [Member]          
Revenues 1,401 2,827 3,486 5,487  
Collaborative and Other Research and Development [Member] | US Department of Health and Human Services [Member]          
Revenues 1,401 2,545 3,486 4,152  
Collaborative and Other Research and Development [Member] | Torii Pharmaceutical Co. [Member]          
Revenues $ 0 $ 282 $ 0 $ 1,335